Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen/Legend’s US pricing and launch plans for Carvykti; Ipsen seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 March 2022, including: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen Pharmaceutical Cos./Legend Biotech Corp.’s US pricing and launch plans for Carvykti; Ipsen SA seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Biotech CEOs Take Assertive Stance On Ukraine War, While PhRMA Remains More Neutral" - Scrip, 1 Mar, 2022.)

(Also see "Scrip’s Rough Guide To Targeted Protein Degradation" - Scrip, 28 Feb, 2022.)

(Also see "Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti" - Scrip, 28 Feb, 2022.)

(Also see "Ipsen Seeks Success Outside Big Pharma's Hunting Grounds" - Scrip, 2 Mar, 2022.)

(Also see "Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances" - Scrip, 1 Mar, 2022.)

 

 

 

 
 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel